CLINICAL EFFICACY AND TRANSFER OF BMY-28100 TO BLOOD AND SKIN

We performed basic and clinical studies on BMY-28100 in dermatological infections, with the following results. 1. Five-hundred mg of BMY-28100 was orally administered to 9 patients with benign skin tumors, and 2h later the blood level of the drug and its transfer to the skin were determined. The mea...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 37; no. Supplement3; pp. 823 - 826
Main Authors SHINOMIYA, SHIGERU, TODA, KIYOSHI, OHTA, MIDORI, SHONO, SHIGEAKI, OSAKU, AYA
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1989
公益社団法人 日本化学療法学会
Subjects
BMY-28100皮膚感染症
皮膚組織濃度
臨床検討
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.37.Supplement3_823

Cover

More Information
Summary:We performed basic and clinical studies on BMY-28100 in dermatological infections, with the following results. 1. Five-hundred mg of BMY-28100 was orally administered to 9 patients with benign skin tumors, and 2h later the blood level of the drug and its transfer to the skin were determined. The mean concentration of BMY-28100 was 9.16μg/ml in blood and 2.24μg/g in dermal tissue. 2. We carried out a clinical study on 12 patients with skin disease. The clinical efficacy rate was about 92%.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.37.Supplement3_823